Source: International Congress 2019 – ALERT: Abstracts Leading to Evolution in Respiratory Medicine Trials: Interstitial lung diseases and pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
R. Zamanian (Stanford, United States of America), D. Badesch (Denver, United States of America), L. Chung (Stanford, United States of America), R. Domsic (Pittsburg, United States of America), T. Medsger (Pittsburg, United States of America), A. Pinckney (Durham, United States of America), L. Keyes-Elstein (Durham, United States of America), C. D'Aveta (Durham, United States of America), M. Spychala (Durham, United States of America), J. White (Rochester, United States of America), P. Hassoun (Baltimore, United States of America), F. Torres (Dallas, United States of America), J. Molitor (Minneapolis, United States of America), D. Khanna (AnnArbor, United States of America), H. Maeker (Stanford, United States of America), B. Welch (Bethesda, United States of America), E. Goldmuntz (Bethesda, United States of America), M. Nicolls (Stanford, United States of America), . On Behalf Of Asco1 Investigators (- , United States of America). Late Breaking Abstract - Safety and efficacy of B-cell depletion with rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension.. 1884

Member's Comments

No comment yet.

Related content which might interest you: Safety and efficacy of immunoadsorption as an add-on to medical treatment in patients with idiopathic pulmonary arterial hypertension Source: International Congress 2017 – Outcomes and new treatment strategies in pulmonary hypertension Year: 2017 Stress-Doppler-Echocardiography for early detection of systemic sclerosis associated pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 Upfront combination therapy in the treatment of scleroderma-associated pulmonary arterial hypertension: Results of an open label trial Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management Source: Eur Respir Rev 2010 19: 314-320 Year: 2010 Long-term prognosis of patients with systemic lupus erythematosus-associated pulmonary arterial hypertension: CSTAR-PAH cohort study Source: Eur Respir J, 53 (2) 1800081; 10.1183/13993003.00081-2018 Year: 2019 Long-term safety of a new formulation of epoprostenol in pulmonary arterial hypertension Source: Annual Congress 2013 –Pulmonary circulation: clinical diagnosis, imaging, biomarkers and treatment Year: 2013 Long-term safety and efficacy of imatinib in pulmonary arterial hypertension Source: Annual Congress 2012 - Pulmonary circulation: clinical treatment Year: 2012 Safety of corticosteroid therapy in patients with pulmonary sarcoidosis Source: International Congress 2017 – The many faces of sarcoidosis Year: 2017 Response to PAH specific therapy in systemic sclerosis patients with extensive parenchymal changes and pulmonary hypertension Source: Virtual Congress 2020 – Pulmonary hypertension in lung diseases Year: 2020 Idiopathic pulmonary fibrosis: efficacy of complex immunosuppressive therapy by cyclophosphamide and corticosteroids Source: Annual Congress 2009 - Various backgrounds in diffuse parenchymal lung disease Year: 2009 Risk assessment in patients with systemic sclerosis and pulmonary arterial hypertension Source: Eur Respir J, 52 (4) 1801745; 10.1183/13993003.01745-2018 Year: 2018 Treatment of early systemic sclerosis associated pulmonary arterial hypertension with endothelin receptor antagonists improves survival Source: Annual Congress 2007 - Clinical aspects of pulmonary arterial hypertension Year: 2007 Exercise pulmonary hemodynamics in systemic sclerosis patients – Implications for outcome Source: International Congress 2016 – Pulmonary hypertension: exercise, haemodynamics, and physiology Year: 2016 Gas transfer relates to pulmonary haemodynamics and survival in pulmonary arterial hypertension associated with systemic sclerosis Source: Eur Respir J 2007; 30: Suppl. 51, 344s Year: 2007 Late Breaking Abstract - Evaluating the feasibility, safety, and efficacy of senolytics in idiopathic pulmonary fibrosis Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings Year: 2019 Identifying early pulmonary arterial hypertension in patients with systemic sclerosis Source: Eur Respir J, 51 (4) 1800495; 10.1183/13993003.00495-2018 Year: 2018 Acute haemodynamic effects of adaptive servoventilation therapy in patients with pulmonary arterial hypertension and patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Trends in systemic sclerosis and systemic sclerosis-related pulmonary arterial hypertension mortality in the USA Source: ERJ Open Res, 6 (2) 00309-2019; 10.1183/23120541.00309-2019 Year: 2020 Pulmonary arterial hypertension in systemic sclerosis: a distinctive endotheliopathy? Source: Eur Respir J 2010; 35: 223-224 Year: 2010